Amyotrophic Lateral Sclerosis: New Suggestions of Pathophysiology and Treatments

Taruna Ikrar


Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that specifically affects motor neurons and leads to a progressive and ultimately fatal loss of functions, resulting in death typically within 3 to 5 years of diagnosis. The disease starts with a focal center of weakness, such as one limb, and usually spreads to other extremities, the brain, and often kills by affecting the respiratory muscles. Recent studies reveal a trend towards an increase in the ALS mortality rate, but the significance of this trend remains unclear. Recent ALS incidence studies have given new insight into ALS epidemiology. ALS seems to be distributed uniformly in different countries, with age-specific incidence rates showing a progressive increase up to the 60–79 age group. The pathophysiological mechanisms underlying the development of familial ALS seem multifactorial with emerging evidence of a complex interaction between genetic and molecular pathways. This review provides new insights into the two different form of ALS which primarily highlights epidemiology, clinical manifestations, pathophysiological, current state of ALS therapy and what the best directions are regarding future ALS research. Future directions to treat and manage ALS via stem cell therapy, possibly new drug discoveries, and diet are given.


Amyotrophic lateral sclerosis (ALS), neuro-degenerative, genetics, stem cell

Full Text:



Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, Muravov O, Horton K. Prevalence of Amyotrophic Lateral Sclerosis - United States 2012-2013. MMWR Surveill Summ 2016:65(8);1-12.

Wanga MD, Littlea J, Gomesc J, Cashmanf N, Krewskia D. Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. NeuroToxicology 2016: 30116-4.

Huisman H, Sonja W, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture recapture methodology. J Neurol Neurosurg Psychiatry 2011: 82:1165-1170.

Chiòa G A, Logroscinob, Traynorc BJ, Collinsd J, Simeoned JC, Goldsteine LA, and Whitef LA. Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature. Neuroepidemiology. 2013: 41(2); 118–130.

Ole-Bjørn Tysnes. Epidemiology and Management of ALS. ACNR 2004: 4; 8-9.

CDC. Prevalence of Amyotrophic Lateral Sclerosis United States, 2010–2011 HHS. Surveillance Summaries 2014: 63- 7.

Ettore B, Logroscino G, et. al. The epidemiology of ALS and the role of population-based registries. Biochimica et Biophysica Acta 2006: 1762; 1150–1157.

Wilhelmina-de-Jong S. Amyotrophic lateral sclerosis: epidemiology, risk factors and treatment. Ridderprint, Ridderkerk 2012: 1-185.

Coupé C, Gordon P. Amyotrophic Lateral Sclerosis Clinical Features, Pathophysiology and Management. Touch Medical Media 2013: 38-44.

Matthew C Kiernan, Steve Vucic, Benjamin C Cheah, Martin R Turner, Andrew Eisen, Orla Hardiman, James R Burrell, Margaret C Zoing. Amyotrophic lateral sclerosis. lancet, 2011: 377; 942-955.

Schwontkowski D. Dr David Steenblock Reveals Key to Brain Repair. Health & Fitness Magazine 2001: 1-7.

Steenblock, D. Hypothesis: Osseous Spinal Injury and Reinjury as a Risk Factor, Biomarker, and Etiological Factor in Sporadic ALS. Townsend Letter 2016: 10; 10-12.

Bensimon et. al. A controlled trial of riluzole in ALS. NEJM 1994: 12-13.

David R. Borchelt. Amyotrophic Lateral Sclerosis. Are Microglia Killing Motor Neurons? NEJM 2006: 1611-1613.

Paul H. Gordon. Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials. Amyotrophic Lateral Sclerosis 2013: 295-310.

Shoji Tsuji, et al. Mutations in COQ2 in Familial and Sporadic Multiple-System Atrophy. N Engl J Med 2013: 369: 233-44.

Petrou P, Gothelf Y, Argov Z, Gotkine M, et. al. Safety and Clinical Effects ofMesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients with Amyotrophic Lateral Sclerosis Results of Phase 1/2 and 2a Clinical Trials. JAMA Neurol. 2016:73(3); 337-344.

Letizia Mazzini, Franca Fagioli, Riccardo Boccaletti,el. Al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. ALS and another motor neuron. disorders 2003: 4; 158–161.

Marconi S, Bonacorsa, Scampi, et al: Systemic Treatment with Adipose-derived Mesenchymal Stem Cells Ameliorates Clinical and Pathological Features in The Amyotrophic Lateral Sclerosis Murine Model. Neuroscience 2013: 333–343.

Storkebaum E, Lambrechts D, Dewerchin M. Treatment of motor neuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nature Neurosciences 2005: 8; 85-90.

Dunckley T, Huentelman MJ., David W. Craig, et. al. Whole-Genome Analysis of Sporadic Amyotrophic Lateral Sclerosis. N Engl J Med 2007: 357; 775-88.

Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology, 2006:66(5): 647–53.

Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010: 81(4); 385–90.

Marin B, Gil J, Preux PM, Funalot B, Couratier P. Incidence of amyotrophic lateral sclerosis in the Limousin region of France, 1997-2007. Amyotroph Lateral Scler 2009:10(4); 216–20.

Ragonese P, Filippini G, Salemi G, et al. Accuracy of death certificates for amyotrophic lateral sclerosis varies significantly from north to south of Italy: implications for mortality studies. Neuroepidemiology 2004: 23(1–2); 73–7.

Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002:59(2); 280–2.

Gordon PH, Mehal JM, Holman RC, et al. Incidence of Amyotrophic Lateral Sclerosis Among American Indians and Alaska Natives. JAMA Neurol 2013:1–5.

Kurland LT, Hirano A, Malamud N, Lessell S. Parkinsonism dementia complex, an endemic disease on the island of Guam. Clinical, pathological, genetic and epidemiological features. Trans Am Neurol Assoc 1961:86; 115–20.

Steenblock D, Payne AG. Umbilical Cord Stem Cell Therapy. Basic Health Publication, Inc. 2006: Laguna Beach, CA.

Alonso A, Logroscino G, Jick SS, Hernan MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol 2009:16(6);745–51.

Fang F, Valdimarsdottir U, Bellocco R, et al. Amyotrophic lateral sclerosis in Sweden, 1991-2005. Arch Neurol 2009:66(4); 515–9.

Logroscino G, Traynor BJ, Hardiman O, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008:79(1); 6–11.

Gordon P, Mitsumoto H, Przedborski S, Gordon P. History of ALS in Amyotrophic Lateral Sclerosis. New York: Taylor & Francis Group 2006: 1–16.

Kasarskis EJ, Winslow M. When did Lou Gehrig’s personal illness begin? Neurology 1989: 39(9); 1243–5.

Scarmeas N, Shih T, Stern Y, et al. Premorbid weight, body mass, and varsity athletics in ALS. Neurology 2002:59(5);773–5.

Steenblock D. The Real Cause of ALS, Stem Cells, Helping The Body Reverse Neurological Brain Disorders, Parkinson’s Disease, Alzheimer’s. Disease Extreme Health Radio 2015: 1-7.

Agosta E, Alchalabi A, Filippi M, et. al. The El Escorial criteria: Strengths and weaknesses. Informa Healthcare 2014:1-7.

Vora M, Kumar S, Sharma S. Advanced magnetic resonance neuroimaging in bulbar and limb onset early amyotrophic lateral sclerosis. J. Neurosciences Rural Practice 2016:7;102-108.

Steenblock D. Specializing in Stem Cell Treatments, Adult Stem Cells & Stem Cell Therapies. TLS 2013:1-10.

Wicks P. Reassessing received wisdom in ALS-pain is common when studied systematically. Eur J Neurol 2012: 19(4):531-2.

Sutedja NA, Veldink JH, Fischer K, et al. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler 2009:302–9.

Steenblock DA. New Approaches to Stroke and Brain Injury Repair. Physical Therapy and Rehabilitation Medicine 2001: 11-12.

McGuire V, Longstreth WT Jr, Nelson LM, et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol 1997:145(12); 1076–88.

Owen, RW, B Spiegelhalder, H. Bartsch. Generation of reactive oxygen species by the fecal matrix. Gut 2000; 46:225-232.

Salazar-Grueso EF, Roos RP. Amyotrophic lateral sclerosis and viruses. Clin Neurosci, 1995:3(6); 360–7.

Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology 2003: 22(4); 217–28.

Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009:65; S3–S9.

Dupuis L, Gonzalez de Aguilar JL, di SF, et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002:10(3); 358–65.

Pradat PF, Bruneteau G, Gonzalez de Aguilar JL, et al. Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol 2007:62(1); 15–20.

Banerjee V, Shani T, Katzman B, Vyazmensky M, et. al. Superoxide Dismutase 1 (SOD1)-Derived Peptide Inhibits Amyloid Aggregation of Familial Amyotrophic Lateral Sclerosis SOD1 Mutants. ACS Chem. Neurosci 2016: 1-7

Robert C. C. Mercer, Li Ma, Joel C. Watts, Robert Strome, et. al. The Prion Protein Modulates A-type K+ Currents Mediated by Kv4.2 Complexes through Dipeptidyl Aminopeptidase-like Protein 6. J Biol Chem 2013: 2519-28.

Mulligan VK, Chakrabartty A. Protein misfolding in the late onset neurodegenerative diseases: Common themes and the unique case of amyotrophic lateral sclerosis. Proteins 2013: 5-15.

Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis, ALS/Riluzole Study Group. N Engl J Med 1994: 330(9); 585–91.

Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012: 3.

Kiernan MC, Vucic S, Cheah BC, et. al. Amyotrophic lateral sclerosis. The lancet 2011:(377) 9769; 942–955.

Walley T. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing? CNS Drugs 2004:18(1); 1–12.

R.G. Miller, Rosenberg, Gelinas, Mitsumoto,et. al. Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Neurology 1999: 52; 1311.

Gordon PH, Mitsumoto H. Chapter 20 Symptomatic therapy and palliative aspects of clinical care. Handb Clin Neurol 2007:82; 389–424.

Haute Autorité. Prise en charge de personnes atteintes de sclérose latéral amyotrophique; conférence de consensus 2006: 1-15.

Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009:73(15); 1227–33.

Wegorzewska, Bell S, Nigel J. Cairns. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. PNAS 2009: 44;18809–18814.

Sanjay Kumar 1 and Muhammad Ashraf 2. Tadalafil, a Phosphodiesterase Inhibitor Protects Stem Cells Over Longer Period Against Hypoxia/Reoxygenation Injury Through STAT3/PKG-I Signaling. Stem Cells and Development 2015: 24; 1-9.

Ikrar T, Guo N, K He, A Besnard, et. al. Adult neurogenesis modifies excitability of the dentate gyrus. Frontiers in neural circuits 2013: 7-17.

Wolfe, L. E, Joyce, N. C., McDonald C. M, Benditt, J.O, Finder, J. Management of pulmonary complications in neuromuscular disease. Physical Medicine and Rehabilitation Clinics 2012: 234; 829-853.

Gruis, K. L, Brown, D. L, Lisabeth, L.D, Zebarah, V.A, Chervin, R. D, Feldmon, E. L. “Longitudinal assessment of non-invasive positive pressure ventilation adjustments in ALS patients”, J. Neurological Sciences 2006:247(1); 59-63.

Petrou P, Gothelf Y, Argov Z, Gotkine M, et. al., “Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients with Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials”, JAMA Neurol 2016: 73(3); 337-44.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.